Thank you for correcting your previous comment that you thought there was a different level of evidence pyramid for surgical products vs medications. In all cases a RCT (or Meta-analysis of) in terms of the reliability of the evidence is Gold Standard and I am glad you found my reference helpful.
Now that you have clarified that you were instead referring to the specific situation where it may not be deemed appropriate to run a Gold Standard RCT I have no problem with your position upon clarification. I have read the first reference you provided previously and agree that when a proper RCT can not be conducted case studies are an appropriate alternative for surgical intervention.
To bring it back to mesoblast: like with the design of surgical/devices trials, there are also times in pharmaceuticals or biologics where a RCT may not be ideal/appropriate and a sponsor/regulator can make a case for a trial design further down the hierarchy in terms of reliability of evidence. Such instances include (a life threatening disease where SOC has failed/ or no approved therapies, extremely rare diseases may not practically warrant running a full RCT etc). These are not easy decisions I would imagine and involve the input of complex ethical issues. For that is really one of the primary reason that RCT may not be selected. At times there may be a case for the greater good that it is appropriate to trade off some reliability of evidence in terms of a non-RCT trial design to address some of the most human ethical issues. This will soon be before the FDA, so time will tell soon enough...
Just a bit rich that you heavily critisise Mesoblast on a continual basis as a non-holder for not conducting a RCT in children with SR-aGvHD with severe ethical issues at play; when you also post for surgical products you have a financial interest as to why case studies will unlock new indications. Agree, need to take posts with a grain of salt at times.
To end on a positive, what a great back presentation today! Happy to hear further details on how they are going to run the forthcoming RCT, why HA is not needed as a control as agreed with FDA, targeting patient with CLBP earlier in the disease process - like with CHF - whilst they are inflammed and before they become too fibrotic, additional imaging tools to firm up MOA in additional to biomarkers. Hope you find the recording insightful when you get a chance to watch if you decide to.
- Forums
- ASX - By Stock
- MSB
- Mesoblast hit with 4th shareholder class action
Mesoblast hit with 4th shareholder class action, page-252
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B |
Open | High | Low | Value | Volume |
99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9996 | 99.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
99.5¢ | 18069 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9996 | 0.990 |
2 | 32880 | 0.985 |
4 | 71034 | 0.980 |
2 | 3059 | 0.975 |
7 | 145890 | 0.970 |
Price($) | Vol. | No. |
---|---|---|
0.995 | 1132 | 1 |
1.000 | 9500 | 3 |
1.005 | 35000 | 1 |
1.010 | 58113 | 4 |
1.015 | 46100 | 3 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online